key: cord-0897712-s7wil3mc
authors: Chaomuang, Natthaya; Dede, Adam J.O.; Saokaew, Surasak; Umnuaypornlert, Adinat
title: Effects of home drug delivery on drug-related problems: preliminary evidence for improved patient outcomes during the COVID-19 pandemic in Thailand
date: 2022-01-22
journal: J Am Pharm Assoc (2003)
DOI: 10.1016/j.japh.2022.01.015
sha: 4ae8cf6853d575305ac9378d10eb30adefc82e71
doc_id: 897712
cord_uid: s7wil3mc

Background Drug-related problems cause severe disabilities, premature deaths, and unnecessary costs. Telepharmacy offer easier access to needed medications, preventing DRPs. Adoption has been slow, and it is unclear what aspects of telepharmacy are most important. The COVID-19 pandemic disrupted health services, forcing the rapid adoption of telepharmacy. In Phayao, Thailand, a program was implemented for home delivery of drugs for chronic disease patients. Objectives This study aimed to explore the prevalence and factors associated with DRPs of chronic disease patients who received home drug delivery services. Methods A cross-sectional study was undertaken in Phayao Province located in North Thailand. Simple random sampling was used to select patients from six public hospitals between July and August 2020. Logistic regression was used to analyze multivariate factors that might be related to DRPs. Results 246 participants reported at least one DRP (49.30%). Most participants were female (58.32%) with elementary education (60.72%). Their mean age was 63.69 (SD=12.97) years. The five most common DRPs were changes of drug packaging or drug brands (18.84%), leftover medications of more than two weeks (18.44%), non-adherence (17.43%), having conditions or diseases requiring additional medications (6.81%), and adverse drug reactions (5.21%). Univariate analysis identified number of chronic conditions, diabetes mellitus, dyslipidemia, chronic kidney disease, education level and drug delivery channel as predictors of DRPs. In multivariate analysis, predictors of DRPs were the number of drugs used per day (adjusted odds ratio [aOR] 1.11 [95%CI 1.03-1.19], p=0.004) and dyslipidemia (aOR 1.83 [95%CI 1.18-2.84], p=0.007. Non-adherence was associated with leftover medicines (aOR 4.22 [95%CI 2.44-7.28], p<0.001) Conclusion The present results indicate that home delivery caused no increase and may have caused a decrease in DRPs and patients were highly satisfied. These promising results suggest that home delivery should be continued and further investigated even as the COVID-19 induced emergency subsides.

In general, a DRP is defined as an event or circumstance involving drug therapy that actually 48 or potentially interferes with desired health outcomes in patients. [10] [11] [12] [13] [14] Common examples of 49

DRPs include non-adherence to prescribed drug regimen, patients lacking understanding of 50 how to take their medication or what dosage to take, patients experiencing unexpected adverse 51 side effects or drug interactions 5, 8, 15 , changes of drug packaging or drug brands 16 , and in 52 extreme cases, patients can experience unexpected medical emergencies resulting in 53 hospitalization. 1, 7, 8 The likelihood of DRPs is heightened in situations involving elderly 54 patients, suboptimal prescribing (e.g., overuse, inappropriate use, or underuse of medications, 55 and polypharmacy) , medication errors ( both dispensing and administration problems) , and 56 patient medication non-compliance (both intentional and unintentional). 17 The study of DRPs 57 has often been clouded by inconsistent definitions. In this study, we used a comprehensive 58 definition combining subtypes of DRPs from several different coding systems ( see Methods 59

and Supplementary Table 1 ). This allowed us to capture the full range of DRPs. 60

There have been several strategies to reduce DRPs. One promising approach is the 61 implementation of telepharmacy. Telepharmacy is defined, " as a method used in pharmacy 62 practice in which a pharmacists utilize telecommunications technology to oversee aspects of 63 pharmacy operations or provide patient-care services. " 18 The term telepharmacy acts as an 64 umbrella covering a range of interventions including home delivery of drugs, phone calls with 65 pharmacists, remote monitoring of patient drug use, text messaging apps, and video 66 consultations. 19 Although studies have consistently demonstrated that telepharmacy improves 67 patient outcomes, widespread adoption has been slow. What' s more, because telepharmacy 68 approaches often include several simultaneously applied interventions, it is not clear which 69 aspects of telepharmacy are of most benefit to patients. 20 70

The coronavirus disease 2019 (COVID-19) pandemic has disrupted health services particularly 71 for chronic disease patients. 21 These disruptions have accelerated the adoption of telepharmacy 72 practices. In South Africa, Qatar and China, home delivery pharmacy services have been 73 established. [22] [23] [24] All three of these programs combined home delivery with other aspects of 74 telepharmacy practices (e.g. video consultation). The Qatari study was the only one to evaluate 75

DRPs and found that drug adherence improved for patients in their home delivery program. 23 76 Similar to other countries, Thailand' s health system was disrupted by Telepharmacy was partially implemented to help social distancing and reduce overcrowding 78 of patients in hospitals. Specifically, a home delivery drug refill program ( HDDP) was 79

implemented. The HDDP was implemented country-wide through Thailand's Universal Health 80

Coverage system which covers more than 75% of the population. 25 The initial phase of the 81 HDDP studied here included home delivery without other aspects of telepharmacy. 82

More specifically, the HDDP was implemented on a patient-by-patient basis following a two-83 step procedure. First, doctors and hospital pharmacists reviewed chronic patients' medical 84 records. All chronic disease patients who did not need to be hospitalized for any condition were 85 enrolled in the HDDP. Second, drug delivery was carried out almost entirely by community 86 volunteers and nurses from local clinics (>95%). 87

As the world adjusts to a new normal, it is unclear whether effort should be made to improve 88 and make permanent the emergency telepharmacy programs that have been implemented, or 89 whether we should strive for a return to pre-pandemic standards of care. Today, some hospitals 90 in Thailand have continued the HDDP, but others have reverted to hospital drug distribution. 91

Where it has been continued, Thailand's drug delivery system has been augmented with video, 92 text messaging, and mobile application support, but in the early days of the pandemic, this was 93 not so. Thus, this study aimed to explore the prevalence and factors associated with DRPs of 94 J o u r n a l P r e -p r o o f chronic disease patients who received home drug delivery services during COVID-19 95 pandemic in isolation from other aspects of telepharmacy. 96

A cross-sectional study was undertaken in Phayao Province located in the northern part of 99

Thailand. Older rural Thai people with chronic diseases were our target population. This study 100 was approved by the Institutional Review Board of Phayao Provincial Public Health Office, 101

Phayao province, Thailand ( No. 27/ 2563) . All procedures performed in the present study 102 involving human participants were in accordance with ethical standard procedures. Consent 103 forms were completed by all participants prior their interview. 104

A total of 19,658 patients distributed across 6 regional hospitals in Phayao province were 106 enrolled in the HDDP and comprised our total population of interest. Applying sample size 107 calculation formula 26 with N=19,658 and acceptable sampling error of 0.05 resulted in a target 108 sample size of 392 to which we added 10% to account for incomplete data sets, yielding a 109 target sample size of 431. To further avoid missing data, the research team collected structured 110 interview data using a purpose-developed questionnaire from 500 patients. Data were collected 111 in proportion to total number of patients enrolled in the HDDP at each hospital (supplementary 112 figure 1). Within hospitals, patients were assigned deidentified numbers, and then patients were 113 invited to participate through random number selection until each hospital' s quota had been 114

All patients in the HDDP suffered from chronic diseases, which were defined broadly as 116 conditions that last 1 year or more and that require ongoing medical attention or that limit 117 activities of daily living or both. Common chronic diseases included heart disease, cancer, and 118 diabetes are the leading causes of death and disability. 27 119

Data were collected between July and August 2020. The period of the HDDP was from March 121 to May 2020. Each interview took about 30 minutes. Six primary care pharmacists were trained 122 before interviewing chronic disease patients in their charge in each community. DRPs were 123 identified using a validated survey questionnaire. To identify all possible DRPs, we developed a questionnaire that integrated aspects of five 126 previously published definitions as well as input from our own expert panel (see Supplemental 127 Table 1 ). 10-14 Our expert panel was comprised of two pharmacy researchers, six primary care 128 pharmacists, and four policy makers from the Provincial Public Health Office. This resulted in 129 a more inclusive than typical definition of DRPs. 130

Content validity was assessed using evaluations from three chief pharmacists in the Provincial 131

Health Office of Phayao. Using these ratings, we calculated the index of item objective 132 congruence for each item using the mean across evaluators. Items that had scores higher than 133 or equal to 0.5 were reserved. 134

To enhance reliability of data collection, six primary care pharmacists were trained with a 3-135 hour session before interviewing patients. In addition, a written guide for recording the 136 questionnaires was provided. To quantify reliability, Cronbach' s alpha was calculated to 137 determine interrater reliability among our pharmacists. They all examined the same example 138 questionnaire data to see if they could detect DRPs. 28 This procedure yielded excellent 139 agreement and inter rater reliability was 0.92. 140

The questionnaire was divided into 3 sections: 1. General information about the informant 141 (Table 1) 2. Satisfaction with the HDDP (Table 2 ) and 3. Drug-related problems (Table 3) . 142

In this study, a DRP was defined as an event or circumstance involving drug therapy that 144 actually or potentially interferes with desired health outcomes in the patients 10-14 including 145 changes of drug packaging or drug brands, 16 leftover medications more than 2 weeks 29 and 146 non-adherence and adverse drug reactions. Specific survey questions probed various examples 147 of DRPs ( Table 3) . Non-adherence was defined as patients not taking medications, adjusting 148 the dose themselves, and/ or forgetting to take their medicine. 30 Polypharmacy was defined as 149 taking five or more medications per day. 31 Leftover medicine of more than 2 weeks was defined 150 as prescription drugs that have been oversupplied to patients by more than two weeks. 32 151

The primary outcome of interest in this study was the prevalence of DRPs in chronic disease 153 patients ( who were provided with HDDP) . The secondary outcomes were factors associated 154 with DRPs, non-adherence, and leftover medicines. Assessment of DRPs was based on the 155 validated questions. 156

Demographic information, types of DRPs, and satisfaction with the drug delivery system were 158 summarized using descriptive statistics and were described with frequency and percentages. 159

Continuous data were compared using Student' s t-test, and those results are shown as mean 160 plus/minus standard deviation (SD). Categorical data were compared using chi-square test or 161

Fisher' s exact test based on the criterion that when more than 20% of cells have expected 162 frequencies < 5, we need to use Fisher's exact test. 33 The risk of experiencing a DRP as a 163 function of various predictors in the data set were evaluated using univariate logistic regression, 164

and those results are expressed as odds ratios (OR) and 95% confidence intervals (CI (1.0 %). Most of the participants also received a comprehensive list of their prescription drugs 181 (97.39%) ( Table 1) . 182

Patients were generally satisfied with the HDDP (Table 2) . They reported satisfaction with the 183 information received with HDDP, the method of drug delivery and the timeliness of delivery 184 at rates of 65, 74, and 83%, respectively (Table 2) . 185

Total DRPs in all chronic disease patients who participated in the study are shown in Table 3  186   and Supplementary table 3 . 187

There were 246 participants who reported at least one DRPs (49.30%). The top 5 DRPs were 188 as follows: changes of drug packaging or drug brands (18.84%), leftover medications of more 189 than 2 weeks ( 18. 44%), non-adherence ( 17. 43%), having conditions or diseases requiring 190 additional medication (6.81%), and ADRs (5.21%). 191

Independent variables were tested for significant association with DRP outcomes. The odds of 193 experiencing a DRP were significantly higher as a function of the number of chronic 194 conditions, and for patients with diabetes mellitus, dyslipidemia, or chronic kidney disease. 195 DRP prevalence was also higher for less educated patients and varied across drug delivery 196 channel (Table 1) . 197

For each of these analyses, the association was tested between one DRP component and the 199 composite DRP prevalence excluding the one tested component. Only the four most prevalent 200

DRPs were tested. The prevalence of changes of drug packaging or drug brands, leftover 201 medications more than 2 weeks, non-adherence and ADRs were all associated with the rate of 202 all other DRPs (all p<0.001, see Table 4 (A)). 203

Probable DRP outcomes were predicted using multivariab logistic regression. 

In this study, the prevalence of DRPs of home drug delivery in rural Northern Thailand was 210 49. 30%. The five most common DRPs were; changes of drug packaging or drug brands 211 ( 18. 84%), leftover medications of more than 2 weeks ( 18. 44%), non-adherence ( 17. 43%), 212 J o u r n a l P r e -p r o o f having conditions or diseases requiring additional medications (6.81%), and ADRs (5.21%). 213

Further, non-adherence was associated with a risk of leftover medications. 214 215 Because our program was implemented in an emergency situation, it was not possible to 216 construct a randomized control group, making interpretation difficult. A key question to ask is 217 whether a DRP prevalence of 49. 30% is high or low? We believe this number represents a 218 reduction and points to the general success of the HDDP. Using data from our previous paper, Comparing specific DRP components, we find that there is modest evidence for a reduction of 229 DRPs in our study relative to past literature. For example, a study by Garin et al. (2021) found 230 that 12% of patients experienced ADRs, but in our sample only 5% of patients had ADRs. 35 231 Basheti IA. et al. ( 2016) found that 46. 1% of outpatients with chronic diseases had non-232 adherence, and Chang CT et al. ( 2021) estimated the pooled prevalence of non-adherence to 233 medication was 60. 6% . 6 , 36 By contrast, in our study 17. 43% of patients experienced non-234 adherence. Wilmer CM. ( 2015) found that 20. 2% of patients had conditions or diseases 235 requiring additional medication, but in our study the corresponding figure was only 6.81%. 7 236

Finally, in thinking about the prevalence of DRPs reported here, it is important to note how 237 inclusive our definition of DRP was. Changes in drug packaging or brand was the most 238 commonly reported DRP in our sample, yet it is not included as a DRP in most studies. If these 239

DRPs are subtracted from our results, then the DRP prevalence in our sample drops to 41.28%, 240 which is below most previous reports, further suggesting that home delivery resulted in a drop 241 in DRP prevalence. 242

Although DRP prevalence seemed relatively good in the present sample, this is partially 243 because of how sadly common DRPs are. The most common DRP in this study was change of 244 J o u r n a l P r e -p r o o f drug packaging or drug brand. Drug packaging changes were associated with an increase in all 245 other DRPs ( Table 4 ( A) ) , suggesting that packaging changes can lead to confusion that 246 precipitates other, more dangerous DRPs. Previous studies have also shown that changes of 247 drug packaging or drug brands can lead to confusion and is related to low adherence, and 248 adverse events. 16, 37 In the population studied here, the main reason for packaging and brand 249 changes was due to substitution of equivalent drugs necessitated by supply shortages. To 250 mitigate this problem, medical personnel must anticipate shortages in order to plan for 251 continuity whenever possible in order to minimize patient impact. 24 When continuity is not 252 possible, it is imperative that brand changes are marked with pharmacist consultation and clear 253 labeling. Specifically, we suggest that brand changes be marked with stickers reading, 254 "Identical type and dose of drugs but the brand was altered". 255

The second most common DRP we observed was leftover medications. Leftover medicine was 256 associated with non-adherence which was similar to previous reports. 32, 34, 38 Leftover 257 medications can be caused by several factors including: patients' discontinuing their drug 258 regimens, adverse effects from drugs, errors of prescription, order or supply problems, over-259 collection in the past, patients' being left to self-manage complex regimes, and changes in 260 medical condition. 39, 40 Leftover medication is a common problem, with as many as 74% of 261 outpatients reporting leftover medication. Similar to our observations, it has been reported that 262 anti-hypertensive drugs represent the highest quantity and value of drug waste followed by 263 anti-diabetic agents. 41 Unwanted and unused medications accumulate in patients' homes and 264 lead to unnecessary costs and harmful effects. 29 Community awareness programs and 265 pharmacist collections of unwanted medications could go a long way to alleviating this 266 problem. 39 267

The third most common DRP was non-adherence, which itself can lead to other DRPs. 268

Considering that we observed a relatively low non-adherence prevalence 17.4% compared with 269 comparable results in Thailand 42-45% , home drug delivery may already be a promising 270 avenue for reduction of non-adherence problems. 8, 9 It is likely that augmenting the drug 271 delivery program with other aspects of telepharmacy ( e. g. video and text messaging with 272 pharmacists) will reduce non-adherence even further. 24 273

Although born out of the exigency of the Covid-19 crisis, we believe that the drug delivery 275 program described here has been a positive forward step in the implementation of 276 J o u r n a l P r e -p r o o f telepharmacy. Telepharmacy is a healthcare service growing in popularity. In previous studies, 277 it was found that when telepharmacy is used in health systems, it has been shown to reduce 278 overall costs and help patients access treatment more conveniently. [42] [43] [44] Telepharmacy 279 increases satisfaction ratings of both patients and healthcare providers, including pharmacists, 280 nurses, physicians and pharmacy technicians. 44, 45 Telepharmacy can also help pharmacists 281 monitor DRPs, improve medication compliance, reduce the number of medication errors, and 282 decrease ADRs, costs and treatment failures. 20, 46 These gains are likely to be particularly large 283 in rural areas like the region studied here. This is because telepharmacy makes remote areas 284 more reachable by healthcare professionals. 42 285 286 Home drug delivery is a central service in many telepharmacy programs, but it is generally not 287 studied in isolation. Programs that implement home drug delivery generally also implement 288 remote consultation services and patient monitoring, but the emergency of Covid-19 prohibited 289 development of these resources during the early days of the pandemic. As a result, our study 290 demonstrates that HDDP might reduce DRPs and patients had overwhelmingly positive views. 291

This is a particularly interesting result considering that pharmacists implementing 292 telepharmacy initiatives in the United States have often faced problems with loss of privacy 293 and confidentiality, low digital literacy skills in the elderly, lack of affordable and user friendly 294 platforms to support telepharmacy, and a lack of policy to implement telepharmacy. 19, 47 Our 295 study demonstrates that these challenges need not stymie attempts to implement at least some 296 part of a telepharmacy program as simply adding a home delivery option may already improve 297 outcomes alone. However, these effects may be lost over a longer period, and the program 298 reported here has now been augmented with remote consultation and monitoring services. 299

Taken together, these results suggest that HDDP are an improvement over traditional pharmacy 300

practices, but our survey also revealed challenges that can be addressed to further improve 301 telepharmacy practices. 302 303

Strengths of the study were as follows. First, the current Covid-19 situation created a rare 305 opportunity to study the effect of drug delivery on DRPs in isolation from other features of 306 telepharmacy. Second, primary care pharmacists are familiar with their local patients, and this 307 helped them act as effective data collectors, obtaining accurate information. Moreover, most 308 participants were elderly so the data collection method we used was appropriate for our 309 samples. Third, the questions posed were assessed by three chief pharmacists in the Provincial 310

Health Office to ensure that they were applicable to primary care pharmacy in Phayao which 311 was the setting of the study. 312 313

Our study had limitations. First, although well-powered to make inferences about this region, 315 our data are limited to the rural developing region we studied. It is unclear how these results 316 might generalize to other areas. Therefore, multicenter studies are needed to confirm our 317

conclusions. Second, data on over-the-counter medicines may be biased. For example, the 318 participants may not report their use of over-the-counter medicines. This possibility may lead 319 to an underestimation of the level of DRPs in the participants and the number of products used. 320

Third, the HDDP studied here did not specify criteria for screening appropriate patients. Thus, 321 patients may have had more variable disease severity than in other studies, which could have 322 resulted in an increased prevalence of DRPs. However, as this factor would have, if anything, 323 biased our results towards higher prevalence, it is all the more striking that we observed a 324 relatively low prevalence, and the results from this study reflected the reality that occurs in the 325 workflow of drug delivery. 326

Future studies should make clear whether clinical outcomes of implementing home drug 327 delivery are not worse than clinical outcomes under traditional conditions before widespread 328 adoption of this strategy. Furthermore, appropriate criteria for choosing patients should take 329 into consideration disease severity and other associated factors that might cause DRPs. 330

Although the HDDP effectively helped Thailand navigate the pandemic and seems to improve 331 patient outcomes, delivery costs will likely prohibit its continuation. However, if improvements 332 in DRPs result in savings on future patient care and better outcomes, then delivery costs may 333 be well worth it, and future research should examine long-term financial costs and benefits of 334 drug delivery. 335

Home drug delivery was implemented during the Covid-19 emergency in rural Thailand, the 337 results were favorable. Patients were highly satisfied and said they would like to continue home 338 delivery even after the Covid-19 emergency is over. DRP prevalence was no higher than under Table 3 Drug-related problems identified in chronic disease patients J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f

Drug-Related Morbidity and Mortality: Updating the Cost

Adverse drug 355 reactions as cause of admission to hospital: prospective analysis of 18 820 patients

Drug-related hospital admissions

Drug-related problems in a sample 360 of outpatients with chronic diseases: a cross-sectional study from Jordan. Ther Clin Risk 361 Manag

Drug-related 363 problems and associated factors in Ethiopia: a systematic review and meta-analysis

Related Problems and Complementary and Alternative Medicine Use in Malaysia: A 367 Systematic Review and Meta-Analysis of 37,249 Older Adults

Drug-related problems in a clinical setting: a literature review and cross-sectional study 371 evaluating factors to identify patients at risk

Problems Identified at Patients' Home: A Prospective Observational Study in a Rural Area of 375 Thailand

ASHP guidelines on a standardized method for pharmaceutical care. American Society 380 of Health-System Pharmacists

Pharmaceutical care practice

Opportunities and responsibilities in pharmaceutical care

Drug-related problems: identification, characteristics and pharmacy 389 interventions (dissertation)

Drug related problems: An over view of various 392 classification systems

Pharmaceutical packaging can induce confusion

Assessment of medication-related problems in geriatric 395 patients of a rural tertiary care hospital

American Society of Health-Systems Pharmacists

Current practices and state 402 regulations regarding telepharmacy in rural hospitals

World Health Organization. 2020. Information note: NCDs and Covid-19

Home delivery of medication during 409

South Africa: Short report. Afr J Prim Health Care Fam 410 Med

Qatar's Primary Health Care Medication Home Delivery Service: 413 A Response Toward COVID-19

Providing pharmacy services 415 during the coronavirus pandemic

Telehealth, telemed, telepharmacy seen as new normal in Universal health Coverage 417 (UHC): NHSO. Available from

About chronic diseases: National Center for Chronic Disease Prevention 423 and Health Promotion (NCCDPHP)

Assessing the Reliability of Attitude 426 Scale by Cronbach's Alpha

The Cost of Unused Medications

Patient medication adherence: measures in daily practice

What is polypharmacy? A 431 systematic review of definitions

Leftover medications in patients 433 with chronic diseases from home health care visits: a community study in Bangkok

Statistical notes for clinical researchers: Chi-squared test and Fisher's exact 436 test. Restor Dent Endod

Survey of leftover drugs among 438 patients with chronic diseases at Bangsaphan Hospital, Prachuap Kirikhan

Drug related 441 problems in clinical practice: a cross-sectional study on their prevalence, risk factors and 442 associated pharmaceutical interventions

Associations between patient 444 factors and medication adherence: A Jordanian experience

The multisensory design of pharmaceuticals and their packaging. Food 447 Quality and Preference

Survey of leftover drugs and drugs use behavior among patients with chronic disease 450 in Nonng Pak Long

Disposal 452 Practice for Unused Medications among the Students of the International Islamic University 453

Reducing medicines waste in the community. Primary 455 Health Care Research and Development

A survey of the quantity and value of leftover 457 medicines in outpatients, Department of Internal Medicine Siriraj Hospital

Telepharmacy Services: Present Status and Future 461 Perspectives: A Review

Telepharmacy for the management of cardiovascular patients in 463 the community

Investigating 467 Pharmacists' Views on Telepharmacy: Prioritizing Key Relationships, Barriers, and Benefits

Rural inpatient telepharmacy consultation 470 demonstration for after-hours medication review

Telepharmacy during COVID-19: A Scoping 472